View Cart  

Jazz Gets Warning Letter for Minimizing Risks of Schizophrenia Drug in Patient Promo

A A
Jazz Pharmaceuticals received an FDA warning letter for overstating the benefits and minimizing or omitting the risks of its schizophrenia drug FazaClo in a patient brochure.

To View This Article:

Login

Subscribe To Drug Industry Daily